Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.

Grifoni A, Moore E, Voic H, Sidney J, Phillips E, Jadi R, Mallal S, De Silva AD, De Silva AM, Peters B, Weiskopf D, Sette A.

Front Immunol. 2019 Jul 5;10:1568. doi: 10.3389/fimmu.2019.01568. eCollection 2019.

2.

Family-centred oral health promotion through Victorian child-health services: a pilot.

Heilbrunn-Lang AY, Carpenter LM, de Silva AM, Meyenn LK, Lang G, Ridge A, Perry A, Cole D, Hegde S.

Health Promot Int. 2019 Apr 21. pii: daz025. doi: 10.1093/heapro/daz025. [Epub ahead of print]

PMID:
31006023
3.

Human antibody response to Zika targets type-specific quaternary structure epitopes.

Collins MH, Tu HA, Gimblet-Ochieng C, Liou GA, Jadi RS, Metz SW, Thomas A, McElvany BD, Davidson E, Doranz BJ, Reyes Y, Bowman NM, Becker-Dreps S, Bucardo F, Lazear HM, Diehl SA, de Silva AM.

JCI Insight. 2019 Apr 18;4(8). pii: 124588. doi: 10.1172/jci.insight.124588. eCollection 2019 Apr 18.

4.

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.

Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.

J Infect Dis. 2019 Jun 19;220(2):219-227. doi: 10.1093/infdis/jiz109.

5.

Longitudinal analysis of acute and convalescent B cell responses in a human primary dengue serotype 2 infection model.

Nivarthi UK, Tu HA, Delacruz MJ, Swanstrom J, Patel B, Durbin AP, Whitehead SS, Pierce KK, Kirkpatrick BD, Baric RS, Nguyen N, Emerling DE, de Silva AM, Diehl SA.

EBioMedicine. 2019 Mar;41:465-478. doi: 10.1016/j.ebiom.2019.02.060. Epub 2019 Mar 8.

6.

Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika.

Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC, Montoya M, Michlmayr D, Kuan G, Balmaseda A, Coloma J, de Silva AM, Harris E.

Nat Commun. 2019 Feb 26;10(1):938. doi: 10.1038/s41467-019-08845-3.

7.

Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa G, Mieczkowski P, Rückert C, Ebel GD, De Silva AD, de Silva AM.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):227-232. doi: 10.1073/pnas.1812055115. Epub 2018 Dec 5.

8.

Deconstruction of an African folk medicine uncovers a novel molecular strategy for therapeutic potassium channel activation.

De Silva AM, Manville RW, Abbott GW.

Sci Adv. 2018 Nov 14;4(11):eaav0824. doi: 10.1126/sciadv.aav0824. eCollection 2018 Nov.

9.

Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells.

Grifoni A, Costa-Ramos P, Pham J, Tian Y, Rosales SL, Seumois G, Sidney J, de Silva AD, Premkumar L, Collins MH, Stone M, Norris PJ, Romero CME, Durbin A, Ricciardi MJ, Ledgerwood JE, de Silva AM, Busch M, Peters B, Vijayanand P, Harris E, Falconar AK, Kallas E, Weiskopf D, Sette A.

J Immunol. 2018 Dec 15;201(12):3487-3491. doi: 10.4049/jimmunol.1801090. Epub 2018 Nov 9.

10.

Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.

Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS.

Cell Rep. 2018 Oct 30;25(5):1214-1224. doi: 10.1016/j.celrep.2018.10.006.

11.

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.

Metz SW, Thomas A, Brackbill A, Xianwen Y, Stone M, Horvath K, Miley MJ, Luft C, DeSimone JM, Tian S, de Silva AM.

PLoS Negl Trop Dis. 2018 Sep 24;12(9):e0006793. doi: 10.1371/journal.pntd.0006793. eCollection 2018 Sep.

12.

Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo.

Willcox AC, Collins MH, Jadi R, Keeler C, Parr JB, Mumba D, Kashamuka M, Tshefu A, de Silva AM, Meshnick SR.

Am J Trop Med Hyg. 2018 Sep;99(3):756-763. doi: 10.4269/ajtmh.18-0156. Epub 2018 Jul 5.

13.

Viral Entry and NS1 as Potential Antiviral Drug Targets.

de Silva AM, Rey FA, Young PR, Hilgenfeld R, Vasudevan SG.

Adv Exp Med Biol. 2018;1062:107-113. doi: 10.1007/978-981-10-8727-1_8. Review.

PMID:
29845528
14.

The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections.

Gallichotte EN, Baric RS, de Silva AM.

Adv Exp Med Biol. 2018;1062:63-76. doi: 10.1007/978-981-10-8727-1_5. Review.

PMID:
29845525
15.

Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.

Swanstrom JA, Henein S, Plante JA, Yount BL, Widman DG, Gallichotte EN, Dean HJ, Osorio JE, Partidos CD, de Silva AM, Baric RS.

J Infect Dis. 2018 May 25;217(12):1932-1941. doi: 10.1093/infdis/jiy063.

16.

Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins.

Kudlacek ST, Premkumar L, Metz SW, Tripathy A, Bobkov AA, Payne AM, Graham S, Brackbill JA, Miley MJ, de Silva AM, Kuhlman B.

J Biol Chem. 2018 Jun 8;293(23):8922-8933. doi: 10.1074/jbc.RA118.002658. Epub 2018 Apr 20.

17.

Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.

Montoya M, Collins M, Dejnirattisai W, Katzelnick LC, Puerta-Guardo H, Jadi R, Schildhauer S, Supasa P, Vasanawathana S, Malasit P, Mongkolsapaya J, de Silva AD, Tissera H, Balmaseda A, Screaton G, de Silva AM, Harris E.

J Infect Dis. 2018 Jul 13;218(4):536-545. doi: 10.1093/infdis/jiy164.

18.

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.

Metz SW, Thomas A, White L, Stoops M, Corten M, Hannemann H, de Silva AM.

Virol J. 2018 Apr 2;15(1):60. doi: 10.1186/s12985-018-0970-2.

19.

Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine.

Gromowski GD, Henein S, Kannadka CB, Barvir DA, Thomas SJ, de Silva AM, Jarman RG.

Vaccine. 2018 Apr 25;36(18):2403-2410. doi: 10.1016/j.vaccine.2018.03.055. Epub 2018 Mar 27.

PMID:
29602701
20.

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.

Gallichotte EN, Baric TJ, Yount BL Jr, Widman DG, Durbin A, Whitehead S, Baric RS, de Silva AM.

PLoS Pathog. 2018 Feb 26;14(2):e1006934. doi: 10.1371/journal.ppat.1006934. eCollection 2018 Feb.

21.

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.

Ramasamy V, Arora U, Shukla R, Poddar A, Shanmugam RK, White LJ, Mattocks MM, Raut R, Perween A, Tyagi P, de Silva AM, Bhaumik SK, Kaja MK, Villinger F, Ahmed R, Johnston RE, Swaminathan S, Khanna N.

PLoS Negl Trop Dis. 2018 Jan 8;12(1):e0006191. doi: 10.1371/journal.pntd.0006191. eCollection 2018 Jan.

22.

Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report.

Goncalves A, Peeling RW, Chu MC, Gubler DJ, de Silva AM, Harris E, Murtagh M, Chua A, Rodriguez W, Kelly C, Wilder-Smith A.

J Infect Dis. 2018 Mar 13;217(7):1060-1068. doi: 10.1093/infdis/jix678.

23.

Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.

Premkumar L, Collins M, Graham S, Liou GA, Lopez CA, Jadi R, Balmaseda A, Brackbill JA, Dietze R, Camacho E, De Silva AD, Giuberti C, Dos Reis HL, Singh T, Heimsath H, Weiskopf D, Sette A, Osorio JE, Permar SR, Miley MJ, Lazear HM, Harris E, de Silva AM.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01504-17. doi: 10.1128/JCM.01504-17. Print 2018 Mar.

24.

Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.

Widman DG, Young E, Nivarthi U, Swanstrom JA, Royal SR, Yount BL, Debbink K, Begley M, Marcet S, Durbin A, de Silva AM, Messer WB, Baric RS.

Sci Rep. 2017 Dec 7;7(1):17169. doi: 10.1038/s41598-017-17355-5.

25.

Rapid, directed transport of DC-SIGN clusters in the plasma membrane.

Liu P, Weinreb V, Ridilla M, Betts L, Patel P, de Silva AM, Thompson NL, Jacobson K.

Sci Adv. 2017 Nov 8;3(11):eaao1616. doi: 10.1126/sciadv.aao1616. eCollection 2017 Nov.

26.

Supervised toothbrushing programs in primary schools and early childhood settings: A scoping review.

Dickson-Swift V, Kenny A, Gussy M, de Silva AM, Farmer J, Bracksley-O'Grady S.

Community Dent Health. 2017 Dec 1;34(4):208-225. doi: 10.1922/CDH_4057Dickson-Swift18. Review.

PMID:
29119741
27.

Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas.

Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, Balmaseda A, Silveira CGT, Maestri A, Costa PR, Durbin AP, Diehl SA, Phillips E, Mallal S, De Silva AD, Nchinda G, Nkenfou C, Collins MH, de Silva AM, Lim MQ, Macary PA, Tatullo F, Solomon T, Satchidanandam V, Desai A, Ravi V, Coloma J, Turtle L, Rivino L, Kallas EG, Peters B, Harris E, Sette A, Weiskopf D.

Front Immunol. 2017 Oct 13;8:1309. doi: 10.3389/fimmu.2017.01309. eCollection 2017.

28.

Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

Grifoni A, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, Martini SR, de Silva AD, Ricciardi MJ, Magnani DM, Silveira CGT, Maestri A, Costa PR, de-Oliveira-Pinto LM, de Azeredo EL, Damasco PV, Phillips E, Mallal S, de Silva AM, Collins M, Durbin A, Diehl SA, Cerpas C, Balmaseda A, Kuan G, Coloma J, Harris E, Crowe JE Jr, Stone M, Norris PJ, Busch M, Vivanco-Cid H, Cox J, Graham BS, Ledgerwood JE, Turtle L, Solomon T, Kallas EG, Watkins DI, Weiskopf D, Sette A.

J Virol. 2017 Nov 30;91(24). pii: e01469-17. doi: 10.1128/JVI.01469-17. Print 2017 Dec 15.

29.

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.

Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E.

MBio. 2017 Sep 19;8(5). pii: e01205-17. doi: 10.1128/mBio.01205-17.

31.

In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.

Metz SW, Gallichotte EN, Brackbill A, Premkumar L, Miley MJ, Baric R, de Silva AM.

Sci Rep. 2017 Jul 3;7(1):4524. doi: 10.1038/s41598-017-04767-6.

32.

Dissecting the human serum antibody response to secondary dengue virus infections.

Patel B, Longo P, Miley MJ, Montoya M, Harris E, de Silva AM.

PLoS Negl Trop Dis. 2017 May 15;11(5):e0005554. doi: 10.1371/journal.pntd.0005554. eCollection 2017 May.

33.

Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.

Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, Lazear HM, de Silva AM.

Emerg Infect Dis. 2017 May;23(5):773-781. doi: 10.3201/eid2305.161630.

34.

Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious Clone.

Gallichotte EN, Menachery VD, Yount BL Jr, Widman DG, Dinnon KH 3rd, Hartman S, de Silva AM, Baric RS.

mSphere. 2017 Feb 22;2(1). pii: e00380-16. doi: 10.1128/mSphere.00380-16. eCollection 2017 Jan-Feb.

35.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

36.

WITHDRAWN: Community-based population-level interventions for promoting child oral health.

de Silva AM, Hegde S, Akudo Nwagbara B, Calache H, Gussy MG, Nasser M, Morrice HR, Riggs E, Leong PM, Meyenn LK, Yousefi-Nooraie R.

Cochrane Database Syst Rev. 2016 Dec 22;12:CD009837. doi: 10.1002/14651858.CD009837.pub3. Review.

37.

Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.

Henein S, Swanstrom J, Byers AM, Moser JM, Shaik SF, Bonaparte M, Jackson N, Guy B, Baric R, de Silva AM.

J Infect Dis. 2017 Feb 1;215(3):351-358. doi: 10.1093/infdis/jiw576.

38.

Unsuspected Dengue as a Cause of Acute Febrile Illness in Children and Adults in Western Nicaragua.

Reller ME, de Silva AM, Miles JJ, Jadi RS, Broadwater A, Walker K, Woods C, Mayorga O, Matute A.

PLoS Negl Trop Dis. 2016 Oct 28;10(10):e0005026. doi: 10.1371/journal.pntd.0005026. eCollection 2016 Oct.

39.

Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.

Metz SW, Tian S, Hoekstra G, Yi X, Stone M, Horvath K, Miley MJ, DeSimone J, Luft CJ, de Silva AM.

PLoS Negl Trop Dis. 2016 Oct 20;10(10):e0005071. doi: 10.1371/journal.pntd.0005071. eCollection 2016 Oct.

40.

Community-based population-level interventions for promoting child oral health.

de Silva AM, Hegde S, Akudo Nwagbara B, Calache H, Gussy MG, Nasser M, Morrice HR, Riggs E, Leong PM, Meyenn LK, Yousefi-Nooraie R.

Cochrane Database Syst Rev. 2016 Sep 15;9:CD009837. doi: 10.1002/14651858.CD009837.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 22;12 :CD009837.

41.

Caries and periodontal disease in Indigenous adults in Australia: a case of limited and non-contemporary data.

de Silva AM, Martin-Kerry JM, McKee K, Cole D.

Aust Health Rev. 2017 Aug;41(4):469-478. doi: 10.1071/AH15229. Review.

PMID:
27567638
42.
43.

Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.

Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman DG, Heise MT, de Silva AM, Baric RS.

MBio. 2016 Jul 19;7(4). pii: e01123-16. doi: 10.1128/mBio.01123-16.

44.

Ticks Take Cues from Mammalian Interferon.

de Silva AM.

Cell Host Microbe. 2016 Jul 13;20(1):3-4. doi: 10.1016/j.chom.2016.06.016.

45.

Child oral health in migrant families: A cross-sectional study of caries in 1-4 year old children from migrant backgrounds residing in Melbourne, Australia.

Gibbs L, de Silva AM, Christian B, Gold L, Gussy M, Moore L, Calache H, Young D, Riggs E, Tadic M, Watt R, Gondal I, Waters E.

Community Dent Health. 2016 Jun;33(2):100-6.

PMID:
27352463
46.

Cohort Profile: The VicGeneration (VicGen) study: An Australian oral health birth cohort.

Johnson S, Carpenter L, Amezdroz E, Dashper S, Gussy M, Calache H, de Silva AM, Waters E.

Int J Epidemiol. 2017 Feb 1;46(1):29-30. doi: 10.1093/ije/dyw024. No abstract available.

PMID:
27143137
47.

Developing a model to assess community-level risk of oral diseases for planning public dental services in Australia.

de Silva AM, Gkolia P, Carpenter L, Cole D.

BMC Oral Health. 2016 Mar 31;16:45. doi: 10.1186/s12903-016-0200-5.

48.

The Emerging Zika Virus Epidemic in the Americas: Research Priorities.

Lazear HM, Stringer EM, de Silva AM.

JAMA. 2016 May 10;315(18):1945-6. doi: 10.1001/jama.2016.2899. No abstract available.

PMID:
26963564
49.

Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.

Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS.

J Virol. 2016 Apr 29;90(10):5090-5097. doi: 10.1128/JVI.00155-16. Print 2016 May 15.

50.

Flying blind: trying to find solutions to Indigenous oral health.

de Silva AM, Martin-Kerry J, Geale A, Cole D.

Aust Health Rev. 2016 Nov;40(5):570-583. doi: 10.1071/AH15157.

PMID:
26691689

Supplemental Content

Loading ...
Support Center